Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com -- Shares of Exelixis dropped 9.1% in premarket trading Monday following the company’s release of data from two separate late-stage cancer trials.
In an update shared earlier Monday, Exelixis provided results from a trial testing its experimental combination treatment for colorectal cancer. The study compared zanzalintinib combined with atezolizumab (Tecentriq) against regorafenib.
At a median follow-up of 18 months, the median overall survival in the intention-to-treat population was 10.9 months for the zanzalintinib-atezolizumab combination versus 9.4 months for regorafenib. The company noted that data for one of the dual primary endpoints were immature at the data cutoff, while the trial had previously met the other primary endpoint in June.
Exelixis plans to complete its first new drug application submission for zanzalintinib in the US in 2025.
Separately, on Saturday, the company released results from a subgroup analysis of a Phase 3 trial for patients with neuroendocrine tumors. The Cabinet trial evaluated Cabometyx against placebo in previously treated advanced NET originating in the lungs or thymus.
According to the company, Cabometyx reduced the risk of disease progression or death by 81% compared to placebo. Median progression-free survival was 8.2 months with Cabometyx versus 2.7 months with placebo.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.